TY - JOUR
T1 - Primary post-transplant lymphoproliferative disorder of the central nervous system
T2 - characteristics, management and outcome in 25 paediatric patients
AU - on behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL), the international Berlin-Frankfurt-Münster (i-BFM) Study Group
AU - Taj, Mary M.
AU - Maecker-Kolhoff, Britta
AU - Ling, Rebecca
AU - Bomken, Simon
AU - Burkhardt, Birgit
AU - Chiang, Alan K.S.
AU - Csoka, Monika
AU - Füreder, Anna
AU - Haouy, Stéphanie
AU - Lazic, Jelena
AU - Miakova, Natalia
AU - Minard-Colin, Veronique
AU - Turner, Suzanne D.
AU - Uyttebroeck, Anne
AU - Attarbaschi, Andishe
N1 - Publisher Copyright:
© 2021 British Society for Haematology and John Wiley & Sons Ltd
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Primary central nervous system (CNS) post-transplant lymphoproliferative disorder (PTLD) in childhood is rare. Twenty-five patients were retrieved from nine European Intergroup for Childhood Non-Hodgkin’s Lymphoma and/or international Berlin–Frankfurt–Münster Study Group members. Types of allografts included kidney (n = 11), liver (n = 4), heart (n = 5), bowel (n = 1) and haematopoietic stem cells (n = 4). Eighteen were male, 16 ≥ 10 years old, 21 had monomorphic disease and 24 solid intracranial tumour masses. Four-year event-free and overall survival rates were 50% ± 10% and 74% ± 9% respectively. This report represents the largest paediatric series of CNS PTLD reported to date, showing favourable survival odds following systemic and intrathecal chemotherapy and rituximab administration.
AB - Primary central nervous system (CNS) post-transplant lymphoproliferative disorder (PTLD) in childhood is rare. Twenty-five patients were retrieved from nine European Intergroup for Childhood Non-Hodgkin’s Lymphoma and/or international Berlin–Frankfurt–Münster Study Group members. Types of allografts included kidney (n = 11), liver (n = 4), heart (n = 5), bowel (n = 1) and haematopoietic stem cells (n = 4). Eighteen were male, 16 ≥ 10 years old, 21 had monomorphic disease and 24 solid intracranial tumour masses. Four-year event-free and overall survival rates were 50% ± 10% and 74% ± 9% respectively. This report represents the largest paediatric series of CNS PTLD reported to date, showing favourable survival odds following systemic and intrathecal chemotherapy and rituximab administration.
KW - central nervous system
KW - outcome
KW - post-transplant lymphoproliferative disorder
KW - transplant
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85103213212&partnerID=8YFLogxK
U2 - 10.1111/bjh.17398
DO - 10.1111/bjh.17398
M3 - Article
C2 - 33764500
AN - SCOPUS:85103213212
SN - 0007-1048
VL - 193
SP - 1178
EP - 1184
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 6
ER -